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INTRODUCTION
Tuberculosis (TB), which is caused by Mycobacterium 
tuberculosis, remains one of the deadliest communicable 
diseases for humans, and it has been identified by the World 
Health Organization (WHO) as one of the three priority 
diseases for drug research and development. In 2013, an 
estimated 9.0 million people developed TB and 1.5 million 
died from the disease, 360 000 of whom were HIV-positive (1). 
However, this problem has become serious as Mycobacterium 
tuberculosis developed resistance against both the first line as 
also the second line drugs. Due to this, there is emergence 
of multi-drug resistant (MDR) and extensively-drug resistant 
(XDR) strains of M. tuberculosis all over the world (2). 
TB may become an incurable disease. Therefore, there is an 
urgent need of finding newer anti-mycobacterial agents to 
combat this problem. A number of studies on the synthesis and 
biological activities of the condensed imidazo[2,1-b]thiazoles 
has been reported since the discovery of novel broad spectrum 
antihelmintic and immunomodulator drug, Levamisole (I) 
(3). In addition, the imidazo[2,1-b]thiazole derivatives of 
Levamisole have been reported as potential antitubercular 
(II) (4, 5), anticancer (III) (6), acetylcholinesterase (AChE) 
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inhibitor (IV) (7), cardiodepressant (V) (8), anthelmintic 
and anti-inflammatory (VI) (9), anti-infectious (VII) (10), 
antiviral (VIII) (11) agents (Figure 1). 
Figure 1. Chemical structures of some bioactive molecules 
bearing an imidazo[2,1-b]thiazole core.
On the other hand, hydrazide-hydrazones (12-17) have 
been a subject of interest in medicinal chemistry as a 
group with a wide range of biological properties including 
antimycobacterial activity. In view of these facts and as a 
continuation of our research on the antitubercular (18-21) and 
the other biological properties of imidazo[2,1-b]thiazoles, 
we here report the synthesis, structural determination and 
antitubercular activity evaluation of some new compounds 
bearing imidazo[2,1-b]thiazole moiety (Figure 2).
Figure 2. N’-(arylidene)-2-[6-(4-bromophenylimidazo[2,1-b]
thiazol-3-yl]acetohydrazide derivatives (3a-i).
MATERIALS AND METHODS
Chemistry
Melting points were determinated with a Büchi B-540 
melting point apparatus (Flawil, Switzerland) in open 
capillaries and are uncorrected. Elemental analyses were 
performed on a LECO CHNS 932 elemental analyser (St.
Joseph, Michigan). IR spectra were recorded on KBr discs, 
using a Perkin Elmer Model 1600 FT–IR spectrophotometer 
(Norwalk, Connecticut, USA). 1H-NMR spectra were 
obtained on Bruker DPX 400 (400 MHz) spectrophotometer 
(Rheinstetten, Germany) using DMSO–d6.
Preparation of ethyl 6-(4-bromophenyl)imidazo[2,1-b]
thiazole-3-acetate hydrobromide (1)  
Compound 1 was obtained according to the procedure 
described by Robert et al. (22).   
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Preparation of 2-[6-(4-bromophenyl)imidazo[2,1-b]
thiazol-3-yl]acetohydrazide (2)
Compound 2 was prepared according to the procedure 
described by Kühmstedt et al. (23). 
General procedure for preparation of N’-(arylidene)-
2-[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]
acetohydrazide derivatives (3a-i) 
A solution of 0.005 mol of 2 and equimolar amount of 
appropriate aldehyde in 30 ml of ethanol was heated for 5h. 
The precipitate obtained was filtered off, washed with boiling 
ethanol.
N’ - ( 2 - ch l o rob e n z y l i d e n e ) - 2 - [ 6 - ( 4 - b ro m o p h e ny l )
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3a) 
Yield: 97%, M.p. 255-258°C, IR (KBr) nmax (cm-1): 3204, 3135, 
3065 (N-H, ar C-H); 1689 (C=O); 1595 (hydrazone C=N). 
1H NMR (400 MHz, DMSO-d6): 3.95, 4.37 (2s, 2H, CH2CO), 
7.11 (s, 1H, C2-H), 7.39- 7.47 (m, 2H, ar C3,5-H), 7.53-7.59 
(m, 3H, Br-Ph C3,5-H, ar C4-H), 7.76-7.81 (m, 2H, Br-Ph 
C2,6-H), 7.95, 8.04 (2dd, 1H, J=7.81, 7.32 Hz, J=1.95, 1.96 
Hz, ar C6-H), 8.30, 8.31 (2s, 1H, C5-H), 8.46, 8.64 (2s, 1H, 
N=CH), 11.84, 12.00 (2s, 1H, CONH). For C20H14BrClN4OS 
calculated: C 50.70, H 2.98, N 11.83; found: C 50.37, H 3.24, 
N 12.16.
N’ - ( 4 - ch l o rob e n z y l i d e n e ) - 2 - [ 6 - ( 4 - b ro m o p h e ny l )
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3b) 
Yield: 97%, M.p. 257-259°C, IR (KBr) nmax (cm-1): 3197, 3131, 
3068 (N-H, ar C-H); 1681 (C=O); 1596 (hydrazone C=N). 
1H NMR (400 MHz, DMSO-d6): 3.92, 4.34 (2s, 2H, CH2CO), 
7.09 (s, 1H, C2-H), 7.49, 7.51 (2d, 2H, J=8.52, 8.87 Hz, ar 
C3,5-H), 7.55, 7.57 (2d, 2H, J=8.51, 7.13 Hz, Br-Ph C3,5-H), 
7.71-7.80 (m, 4H, Br-Ph C2,6-H, ar C2,6-H), 8.05, 8.24 (2s, 
1H, N=CH), 8.26, 8.28 (2s, 1H, C5-H), 11.68, 11.79 (2s, 1H, 
CONH). For C20H14BrClN4OS calculated: C 50.70, H 2.98, N 
11.83; found: C 50.73, H 2.56, N 11.97.
N’-(2-nitrobenzylidene)-2-[6-(4-bromophenyl)imidazo[2,1-b]
thiazol-3-yl]acetohydrazide (3c) 
Yield: 94%, M.p. 242-244°C, IR (KBr) nmax (cm-1): 3566, 
3446 (cry. O-H); 3196, 3131, 3109, 3062 (N-H, ar C-H); 
1672 (C=O); 1566 (hydrazone C=N). 1H NMR (400 MHz, 
DMSO-d6): 3.71, 4.10 (2s, 2H, CH2CO), 6.86, 6.87 (2s, 1H, 
C2-H), 7.32, 7.33 (2d, 2H, J=8.40, 7.82 Hz, Br-Ph C3,5-H), 
7.40, 7.44 (2d, 1H, J=7.49, 7.10, Hz, ar C4-H), 7.52-7.56 (m, 
3H, Br-Ph C2,6-H, ar C5-H), 7.80, 7.84 (2d, 1H, J=8.61, 8.49 
Hz, ar C6-H), 7.89 (d, 1H, J=7.69 Hz, ar C3-H), 8.06 (s, 1H, C5-
H), 8.20, 8.41 (2s, 1H, N=CH), 11.70, 11.87 (2s, 1H, CONH). 
13C-NMR [100 MHz, d ppm, DMSO-d6]: 32.69, 34.16 (CH2), 
109.91, 110.11 (C5), 111.34, 111.59 (C2), 120.58, 120.67 (Br-
Ph C4), 125.46, 125.60 (ar C3), 126.97, 127.36 (C3), 127.44, 
127.50 (Br-Ph C2,6), 128.92, 129.13 (ar C6), 129.48 (ar C1), 
131.44, 131.61 (ar C5),  132.39, 132.42 (Br-Ph C3,5), 134.39, 
134.48 (Br-Ph C1), 134.43, 134.69 (ar C4), 140.00, 143.46 
(N=CH), 145.58, 145.69 (C6), 148.94, 149.03 (ar C2), 149.64, 
149.71 (C7a), 164.60, 170.26 (CONH). For C20H14BrN5O3S.½ 
H2O calculated: C 48.69, H 3.06, N 14.19; found: C 48.70, H 
3.00, N 14.30.
N’-(4-nitrobenzylidene)-2-[6-(4-bromophenyl)imidazo[2,1-b]
thiazol-3-yl]acetohydrazide (3d) 
Yield: 93%, M.p. 266-268°C, IR (KBr) nmax (cm-1): 3563 (cry. 
O-H); 3193, 3143, 3076 (N-H, ar C-H); 1681 (C=O); 1595 
(hydrazone C=N). 1H NMR (400 MHz, DMSO-d6): 3.96, 
4.39 (2s, 2H, CH2CO), 7.11 (s, 1H, C2-H), 7.56 (d, 2H, J=8.46 
Hz, Br-Ph C3,5-H), 7.77, 7.79 (2d, 2H, J=8.44, 7.05, Hz, Br-
Ph C2,6-H), 7.97, 8.00 (2d, 2H, J=8.80, 8.81 Hz, ar C2,6-H), 
8.12, 8.16 (2s, 1H, C5-H), 8.27, 8.28 (2d, 2H, J=8.68, 9.11 
Hz, ar C3,5-H), 8.35, 8.85 (2s, 1H, N=CH), 11.92, 12.02 (2s, 
1H, CONH). For C20H14BrN5O3S.H2O calculated: C 47.81, H 
3.20, N 13.94; found: C 47.14, H 2.55, N 14.29.
N’-(2,4-dinitrobenzylidene)-2-[6-(4-bromophenyl)
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3e) 
Yield: 94%, M.p. 254-257°C, IR (KBr) nmax (cm-1): 3110 (N-H, 
ar C-H); 1674 (C=O); 1600 (hydrazone C=N). 1H NMR (400 
MHz, DMSO-d6): 3.90, 4.28 (2s, 2H, CH2CO), 7.02 (2s, 1H, 
C2-H), 7.47 (d, 2H, J=8.41 Hz, Br-Ph C3,5-H), 7.68 (d, 2H, 
J=8.34 Hz, Br-Ph C2,6-H), 8.19, 8.22 (2s, 1H, C5-H), 8.30 (d, 
1H, J=8.75 Hz, ar C6-H), 8.40-8.61 (m, 2H, ar C5-H, N=CH), 
8.70 (d, 1H, J=2.23 Hz, ar C3-H), 13.06 (s, 1H, CONH). For 
C20H13BrN6O5S calculated: C 45.38, H 2.48, N 15.88; found: C 
45.35, H 1.98, N 16.27.
N’-(5-nitro-2-fur furylidene)-2-[6-(4-bromophenyl)
imidazo[2,1-b]thiazol-3-yl]acetohydrazid (3f) 
Yield: 51%, M.p. 250-252°C, IR (KBr) nmax (cm-1): 3201, 
3019 (N-H, ar C-H); 1674 (C=O); 1566 (hydrazone C=N). 
1H NMR (400 MHz, DMSO-d6): 3.97, 4.33 (2s, 2H, CH2CO), 
7.01, 7.11 (2s, 1H, C2-H), 7.24, 7.29 (2d, 1H, J=3.93, 3.95 
Hz, furan C3-H), 7.56, 7.58 (2d, 2H, J=8.60, 8.98 Hz, Br-Ph 
C3,5-H), 7.75-7.81 (m, 3H, Br-Ph C2,6-H ve furan C4-H), 8.02, 
8.19 (2s, 1H, N=CH), 8.25, 8.27 (2s, 1H, C5-H), 12.02, 12.10 
(2s, 1H, CONH). For C18H12BrN5O4S calculated: C 45.58, H 
2.55, N 14.77; found: C 45.40, H 2.70, N 13.93.
N’-(3-methoxy-4-hydroxybenzylidene)-2-[6-(4-bromophenyl)
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3g) 
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Yield: 86%, M.p. 256-258°C, IR (KBr) nmax (cm-1): 3489 
(O-H); 3138, 3108, 3058 (N-H, ar C-H); 1682 (C=O); 1611 
(hyrazone C=N). 1H NMR (400 MHz, DMSO-d6): 3.78 (s, 
3H, ar C3-OCH3), 3.87, 4.31 (2s, 2H, CH2CO), 6.80, 6.82 (2s, 
1H, C2-H), 7.07-7.12 (m, 2H, ar C2,5-H), 7.27 (d, 1H, J=9.52 
Hz, ar C6-H), 7.54, 7.57 (2d, 2H, J=8.50, 8.63 Hz, Br-Ph 
C3,5-H), 7.74, 7.79 (2d, 2H, J=8.50, 8.45 Hz, Br-Ph C2,6-H), 
7.94, 8.11 (2s, 1H, N=CH), 8.26, 8.28 (2s, 1H, C5-H), 9.38 
(broad s, 1H, ar C4-OH), 11.12, 11.83 (2s, 1H, CONH). For 
C21H17BrN4O3S   calculated: C 51.97, H 3.53, N 11.54; found: 
C 52.39, H 3.48, N 11.74.
N’ - ( 4 - methy lb e n z y l i d e ne ) - 2 - [ 6 - ( 4 - bromophe ny l )
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3h) 
Yield: 93%, M.p. 245-246°C, IR (KBr) nmax (cm-1): 3139, 3078 
(N-H, ar C-H); 1680 (C=O); 1604 (hydrazone C=N). 1H 
NMR (400 MHz, DMSO-d6): 2.34 (s, 3H, ar C4-CH3), 3.90, 
4.32 (2s, 2H, CH2CO), 7.09 (s, 1H, C2-H), 7.25 (d, 2H, J=7.91 
Hz, ar C3,5-H), 7.54-7.63 (m, 4H, Br-Ph C3,5-H, ar C2,6-H), 
7.76, 7.79 (2d, 2H, J=8.51, 8.60 Hz, Br-Ph C2,6-H), 8.03, 
8.20 (2s, 1H, N=CH), 8.27, 8.28 (2s, 1H, C5-H), 11.55, 11.65 
(2s, 1H, CONH). 13C-NMR [100 MHz, d ppm, DMSO-d6]: 
21.89 (CH3), 32.71, 34.22 (CH2), 109.85, 110.15 (C5), 111.15, 
111.39 (C2), 120.56, 120.67 (Br-Ph C4), 127.23 (ar C1), 127.45, 
127.51 (Br-Ph C2,6), 127.23, 127.62 (C3), 127.77, 127.97 (ar 
C3,5), 130.30 (ar C2,6), 132.22, 132.39 (Br-Ph C3,5), 134.39, 
134.50 (Br-Ph C1), 140.62, 140.85 (ar C4), 145.54, 145.69 (C6), 
144.62, 147.95 (N=CH), 149.63, 149.72 (C7a), 164.04, 169.79 
(CONH). For C21H17BrN4OS calculated: C 55.64, H 3.78, N 
12.36; found: C 55.79, H 3.84, N 12.21.
N’-(4-carboxybenzy l idene) -2- [6- (4-bromophenyl )
imidazo[2,1-b]thiazol-3-yl]acetohydrazide (3i) 
Yield: 94%, M.p. 293-295°C, IR (KBr) nmax (cm-1): 3470 (O-
H); 3080 (N-H, ar C-H); 1670 (C=O); 1602 (hyrazone C=N). 
1H NMR (400 MHz, DMSO-d6): 3.95, 4.37 (2s, 2H, CH2CO), 
7.11 (s, 1H, C2-H), 7.55 (d, 2H, J=8.43 Hz, Br-Ph C3,5-H), 
7.77 (d, 2H, J=8.46 Hz, Br-Ph C2,6-H), 7.83-7.97 (m, 4H, ar 
C2,6-H, ar C3,5-H), 8.02, 8.12 (2s, 1H, N=CH), 8.30, 8.32 (2s, 
1H, C5-H), 11.83, 11.95 (2s, 1H, CONH), 13.12 (broad s, 1H, 
COOH). For C21H15BrN4O3S  calculated: C 52.18, H 3.13, N 
11.59; found: C 52.35, H 3.18, N 11.39.
Biological activity
Antimycobacterial assay
In vitro evaluation of antituberculosis activity
Primary screening was conducted at 6.25 mg/ml against 
Mycobacterium tuberculosis H37Rv in BACTEC 12B 
medium using a broth microdilution assay the Microplate 
Alamar Blue Assay (MABA) (24). Compounds exhibiting 
fluorescence were tested in the BACTEC 460 radiometric 
system (25). Compounds effecting <90 % inhibition in 
the primary screen were not generally evaluated further. 
Compounds demonstrating at least 90 % inhibition in 
the primary screen were re-tested at lower concentrations 
against M. tuberculosis H37Rv in order to determine the 
actual minimum inhibitory concentration (MIC) using 
MABA. The MIC was defined as the lowest concentration 
effecting a reduction in fluorescence of 90 % relative to the 
controls. Concurrently with the determination of MICs, 
compounds were tested for cytotoxicity (IC50) in VERO 
cells at concentrations £ 6.25 mg/ml or 10 times the MIC for 
M. tuberculosis H37Rv (solubility in media permitting). After 
72 h exposure, viability was assessed on the basis of cellular 
conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) into a formazan product using 
the Promega CellTiter 96 Non-radioactive Cell Proliferation 
Assay. Compounds for which the selectivity index (IC50: 
MIC ratio) SI >10 were assumed to possess in vitro activity 
confirmed in the BACTEC 460 at 6.25 mg/ml.
Microplate alamar blue susceptibility assay (MABA)
Antimicrobial susceptibility testing was performed in black, 
clear-bottomed, 96-well microplates (black view plates; 
Packard Instrument, Meriden, Connecticut, USA) in order 
to minimize background fluorescence. Outer perimeter 
wells were filled with sterile water to prevent dehydration 
in experimental wells. Initial drug dilutions were prepared 
in either dimethyl sulfoxide or distilled deionized water, 
and subsequent twofold dilutions were performed in 0.1 
ml of 7H9GC (no Tween 80) in the microplates. BACTEC 
12B-passaged inocula were initially diluted 1:2 in 7H9GC, 
and 0.1 ml was added to wells. Subsequent determination of 
bacterial titers yield 1´106 CFU/ml in plate wells for H37Rv. 
Frozen inocula were initially diluted 1:20 in BACTEC 12B 
medium followed by a 1:50 dilution in 7H9GC. Addition of 
1/10 ml to wells resulted in a final bacterial titers of 2.0´105 
CFU/ ml for H37Rv. Wells containing drug only were used 
to detect autofluorescence of compounds. Addition control 
wells consisted of bacteria only (B) and medium only (M). 
Plates were incubated at 37°C. Starting at day 4 of incubation, 
20 ml of 10´ Alamar Blue solution (Alamar Biosciences/
Accumed, Westlake, Ohio, USA) and 12.5 ml of 20% Tween 
80 were added to one B well an done M well, and plates were 
reincubated 37°C. Wells were observed at 12 and 24 h for a 
color change from blue to pink and for a reading of ³ 50,000 
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fluorescence units (FU). Fluorescence was measured in a 
Cytofluor II microplate fluorometer (Perseptive Biosystems, 
Framingham, Massachusetts, USA) in bottom-reading 
mode with excitation at 530 nm and emission at 590 nm. If 
the B wells became pink by 24 h, reagent was added to the 
entire plate. If the well remained blue or £ 50,000 FU was 
measured, additional M and B wells were tested daily until a 
color change occurred, at which time reagents were added to 
all remaining wells. Plates were then incubated at 37°C, and 
results were recorded at 24 h post-reagent addition. Visual 
MICs were defined as the lowest concentration of drug that 
had prevented a color change. For fluorometric MICs, a 
background subtraction was performed on all wells with a 
mean of triplicate M wells. Percent inhibition was defined 
as 1- (test well FU/mean FU triplicate B wells) ´ 100. The 
lowest drug concentration effecting an inhibition of ³90% 
was considered the MIC.
BACTEC radiometric method of susceptibility testing
Inocula for susceptibility testing were either from a positive 
BACTEC isolation vial with a growth index (GI) of 500 or 
more, or a suspension of organisms isolated earlier on a 
conventional medium. The culture was well mixed with a 
syringe and 0.1 ml of a positive BACTEC culture was added 
to each of the vials containing the test compounds (6.25 mg/
ml). The Standard vials contained rifampicin (RMP) (0.25 
mg/ml). A control vial was inoculated with a 1:100 dilution of 
the culture. Each vial was tested immediately on a BACTEC 
instrument to provide CO2 in the headspace. The vials 
were incubated at 37°C and tested daily with a BACTEC 
instrument. When the GI in the control read at least 30, the 
increase in GI (D GI) from the previous day in the control was 
compared with that in the drug vial. The following formula 
was used to interpret the results: 
D GI control > D GI drug = susceptible
D GI control < D GI drug = resistant
If a clear susceptibility pattern (the difference of D GI of 
control and the drug bottle) was not seen at the time the 
control GI was 30 the vials were read for 1 or 2 additional 
days to establish a definite pattern of D GI differences.
RESULTS AND DISCUSSION
In this work, we synthesized a series of N’-(arylidene)-
2-[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]
acetohydrazides. The general procedure for the preparation 
of target compounds 3a-i were described in Scheme 1. 
Scheme 1. The synthetic route for preparation of 3a-i.
The starting compounds 1, 2 were prepared according 
to the literature methods. Thus ethyl 6-(4-bromophenyl)
imidazo[2,1-b]thiazole-3-acetate hydrobromide 1 
(22, 26). was reacted with hydrazine hydrate to give 
the 2-[6-(4-bromophenyl)imidazo[2,1-b]thiazol-3-yl]
acetohydrazide 2 (23, 27). The reaction of appropriate 
aromatic aldehydes with 2 yielded [6-(4-bromophenyl)
imidazo[2,1-b]thiazol-3-yl]acetic acid arylidenehydrazides 
(3a-i) (28). Structures of the synthesized compounds were 
established on the basis of IR, 1H-NMR, 13C-NMR spectral 
data. IR spectra of the compounds showed characteristic 
bands at 3204-3080 cm-1 and 1689-1670 cm-1 corresponding 
to N-H and C=O groups, respectively. Compounds 3g and 
3i showed broad absorption band at 3489 cm-1 and 3470 
cm-1 for O-H, in their respective IR spectra. The absorption 
bands associated with other functional groups appeared in 
the expected regions. The 1H-NMR spectral data were also 
consistent with the assigned structures. 1H-NMR spectra 
of compounds revealed the presence of two geometric 
isomers as concluded from the NH, N=CH and CH2 protons 
resonating as double singlets at about d 12.02-11.12 / 12.10-
11.40, 8.36-7.80 / 8.85-7.96 and d 3.97-3.71 / 4.39-4.10 ppm 
(29), respectively. The signals of these protons appeared as 
a pair of signals owing to different steric arrangement of 
hydrazide-hydrazone functionality in the stereoisomers. 
This steric arrangement might be attributed to the hindered 
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rotation of azomethine linkage (30). It is assumed that the 
N=CH double bond restricts rotation and gives rise to the 
formation of E and Z isomers. 13C-NMR spectra of 3c and 
3h chosen as prototypes verified the proposed hyrazide-
hydrazone structure.
Compounds 3a-3i were tested for in vitro antimycobacterial 
activity against Mycobacterium tuberculosis H37RV using the 
BACTEC 12B medium using a broth microdilution assay, the 
Microplate Alamar Blue Assay (MABA). Rifampicin was used 
as the standard in the antimycobacterial assays. As shown in 
Table 1, all of the compounds exhibited varying degrees of 
inhibition in the in vitro primary screening that was conducted 
at 6.25 mg/ml. The compounds which exhibited < 90% 
inhibition in the primary screen (MIC >6.25 mg/ml) were not 
evaluated further. Compounds 3a, 3c, 3e and 3f effecting >90% 
inhibition in the primary screen at 6.25 mg/ml were re-tested 
at lower concentrations against Mycobacterium tuberculosis 
H37RV to determine the actual MIC using MABA. MIC values 
of these compounds were found to be 6.25 or >6.25 mg/ml 
(Table 2). The level I and level II antimycobacterial activity 
results showed that the most active compound 3e against 
Mycobacterium tuberculosis H37RV at 6.25 mg/ml. The same 
compound was also tested for cytotoxicity (IC50) in VERO 
cells at concentrations equal to and greater than the MIC for 
Mycobacterium tuberculosis H37RV. The IC50 value was found 
at a concentration level of >10 mg/ml for compound 3e and 
the resulting selectivity index (SI= IC50/MIC) was calculated 
as >1.6 (Table 3), showing that this compound not only 
displayed a considerable antimycobacterial activity, but also 
had a remarkable cytotoxicity. 
Table 1. Primary antimycobacterial activity screening results 
of 3a-3i (Level I)
Com-
pound Ar
MIC 
(mg/ml) Assay
Inhibition 
(%)
3a C6H4Cl(2-) <6.25 Alamar 95
3b C6H4Cl(4-) >6.25 Alamar 89
3c C6H4NO2(2-) <6.25 Alamar 91
3d C6H4NO2(4-) >6.25 Alamar 52
3e C6H3NO2(2,4-) <6.25 Alamar 99
3f 5-nitro-2-furyl <6.25 Alamar 98
3g C 6 H 3 ( O C H 3 )
(OH)(3,4-)
>6.25 Alamar 84
3h C6H4CH3(4-) >6.25 Alamar 1
3i C6H4COOH(4-) >6.25 Alamar 86
Rifampicin - 0.25 Alamar 98
Table 2.  MIC assay results of 3a, 3c, 3e and 3f (Level II)
Compound MIC (mg/ml) Inhibition   (%)
3a >6.25 95
3c >6.25 91
3e   6.25 99
3f >6.25 98
Table 3.  Cytotoxicity assay results of 3a, 3c, 3e and 3f (Level II)
Compound MIC (mg/
ml)
I n h i b i t i o n 
(%)
IC50 (mg/ml) SI
3a >6.25 95 9.8 -
3c >6.25 91 1.05 -
3e   6.25 99 >10 >1.6
3f >6.25 98 9.88 -
A remarkable activity was found in compound 3f carrying 
5-nitro-2-furyl moiety. Compound 3a having orto 
chlorophenyl was more active than the corresponding 
orto nitrophenyl derivative. The most active disubstituted 
derivative was 3e having 2,4-dinitrophenyl moiety. The 
results obtained show that some of the prepared and tested 
compounds especially the chlorophenyl/nitrophenyl/furyl 
derivatives may be considered promising for the development 
of new antitubercular agents.
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